Clinical trials in Nijmegen – page 40

579 clinical trials in Nijmegen, The Netherlands across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Nijmegen at a glance

579

clinical trials

Research sites7

Quick filters

579 trials in Nijmegen

Open in trial search

Rectal cancer

Not recruiting

Study on Induction Chemotherapy with Irinotecan, Folinic Acid, Fluorouracil, and Oxaliplatin for Patients with High-Risk Locally Advanced Rectal Cancer

Registered drugNo placebo

Study on Induction Chemotherapy with Irinotecan, Folinic Acid, Fluorouracil, and Oxaliplatin for Patients with High-Risk Locally Advanced Rectal Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Catharina Ziekenhuis Stichting

Contact Research Centre

Gastrooesophageal cancer+1

Not recruiting

Study of Retifanlimab, Capecitabine, and Oxaliplatin for First-Line Treatment in Patients with Metastatic Esophagogastric Cancer

InvestigationalNo placebo

Study of Retifanlimab, Capecitabine, and Oxaliplatin for First-Line Treatment in Patients with Metastatic Esophagogastric Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Retifanlimab
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Angina pectoris

Not recruiting

Study on the Effect of Diltiazem on Angina in Patients with Coronary Microvascular Dysfunction

Registered drug

Study on the Effect of Diltiazem on Angina in Patients with Coronary Microvascular Dysfunction

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cellulose, Microcrystalline
Sponsor:Stichting Radboud University Medical Center

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cetrelimab
Sponsor:Janssen Cilag International

Contact Research Centre

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Cervix carcinoma

Not recruiting

Study on Tisotumab Vedotin, Bevacizumab, Carboplatin, and Pembrolizumab for Patients with Recurrent or Stage IVB Cervical Cancer

Registered drugNo placebo

Study on Tisotumab Vedotin, Bevacizumab, Carboplatin, and Pembrolizumab for Patients with Recurrent or Stage IVB Cervical Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Genmab A/S

Contact Research Centre

Bronchopulmonary aspergillosis

Not recruiting

Study on Imaging Lung Aspergillosis Using Gallium-68 Deferoxamine for Patients with Pulmonary Aspergillosis

Registered drugNo placebo

Study on Imaging Lung Aspergillosis Using Gallium-68 Deferoxamine for Patients with Pulmonary Aspergillosis

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Deferoxamine Mesilate
Sponsor:Stichting Radboud University Medical Center

Contact Research Centre

Myotonic dystrophy

Not recruiting

Safety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)

Investigational

Safety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)

Investigational

The Netherlands

Participants:18–64 years
Substances:Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
Sponsor:Dyne Therapeutics Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Nijmegen

What the registry says about research in the country

01 Neurological Studies

Research focusing on various brain conditions, including glioblastoma imaging techniques and treatments for status epilepticus. Studies investigate brain tissue infiltration patterns and post-cardiac arrest neural conditions.

Brain tumor visualization
Serotonin's role in decision-making
Post-trauma stress disorders

Advanced imaging techniques and therapeutic interventions are being evaluated to improve patient outcomes.

02 Cardiovascular Research

Comprehensive studies examining heart failure prevention and treatment approaches. Investigations include new drug combinations and preventive strategies for cardiovascular events.

Heart failure prevention
Cardiovascular disease management
Post-cardiac arrest care

Clinical trials focus on both preventive measures and acute treatment protocols.

03 Cancer Studies

Innovative research in oncology, particularly focusing on advanced treatment approaches for various cancer types, including breast cancer and leukemia.

Breast cancer imaging
Leukemia treatments
Gastric cancer therapies

Studies evaluate new therapeutic combinations and diagnostic techniques.

04 Metabolic Disorders

Research examining gestational diabetes and obesity treatments, with emphasis on innovative imaging techniques and therapeutic approaches.

Diabetes management
Obesity treatments
Metabolic imaging

Focus on developing personalized treatment strategies.

Back to the Netherlands All countries